Boston Scientific (BSX) PT Raised to $77 at Oppenheimer

Boston Scientific (BSX) PT Raised to $79 at Morgan Stanley

Morgan Stanley analyst Patrick Wood raised the price target on Boston Scientific (NYSE: BSX) to $79.00 (from $72.00) while maintaining a Overweight rating.... More

Boston Scientific (BSX) PT Raised to $73 at Deutsche Bank

Deutsche Bank analyst Pito Chickering raised the price target on Boston Scientific (NYSE: BSX) to $73.00 (from $63.00) while maintaining a Hold rating.... More

Boston Scientific (BSX) PT Raised to $82 at JPMorgan

JPMorgan analyst Robbie Marcus raised the price target on Boston Scientific (NYSE: BSX) to $82.00 (from $72.00) while maintaining a Overweight rating.... More

Boston Scientific (BSX) PT Raised to $82 at RBC Capital

RBC Capital analyst Shagun Singh raised the price target on Boston Scientific (NYSE: BSX) to $82.00 (from $78.00) while maintaining a Outperform rating.

The analyst comments "BSX delivered solid beat with an upside surprise of ~5% and ~10% on sales and EPS, respectively. Given this momentum (+660bps... More

Boston Scientific (BSX) PT Raised to $85 at Mizuho

(Updated - April 25, 2024 7:59 AM EDT)

(Updated - April 25, 2024 6:37 AM EDT)

Mizuho analyst Anthony Petrone raised the price target on Boston Scientific (NYSE: BSX) to $85.00 (from $80.00) while maintaining a Buy rating.

The analyst commented: "The rationale for our BSX upgrade... More

Boston Scientific (BSX) PT Raised to $84 at Baird

(Updated - April 25, 2024 6:46 AM EDT)

Baird analyst David Rescott raised the price target on Boston Scientific (NYSE: BSX) to $84.00 (from $79.00) while maintaining a Outperform rating.

The analyst commented: "BSX's 1Q24 revenue/adj EPS beat (+5%/+10%) was the biggest over the past... More

Boston Scientific (BSX) PT Raised to $86 at Truist Securities

(Updated - April 25, 2024 5:59 AM EDT)

Truist Securities analyst Richard Newitter raised the price target on Boston Scientific (NYSE: BSX) to $86.00 (from $79.00) while maintaining a Buy rating.

The analyst commented: "Our estimates & PT continue to move higher following another excellent print marked... More

Boston Scientific (BSX) PT Raised to $82 at Wells Fargo

Wells Fargo analyst Lawrence Biegelsen raised the price target on Boston Scientific (NYSE: BSX) to $82.00 (from $72.00) while maintaining a Overweight rating.

The analyst comments "Today (4/24), BSX reported Q1 rev/EPS ahead of Street and raised 2024 rev guidance by 250bps at the mdpt to 10-12%.... More

Boston Scientific (BSX) PT Raised to $83 at Canaccord Genuity

Canaccord Genuity analyst William Plovanic raised the price target on Boston Scientific (NYSE: BSX) to $83.00 (from $81.00) while maintaining a Buy rating.... More

Boston Scientific (BSX) PT Raised to $80 at BTIG

BTIG analyst Marie Thibault raised the price target on Boston Scientific (NYSE: BSX) to $80.00 (from $74.00) while maintaining a Buy rating.

The analyst comments "After a record-setting 2023, Boston Scientific is starting 2024 at an even faster pace. BSX reported Q1 revenue of $3.856B (+13.8% y/y rep., +13.1% org.) and adj. EPS of $0.56 (consensus $3.684B and $0.51), well above its guidance... More

Boston Scientific (BSX) PT Raised to $83 at Stifel

(Updated - April 24, 2024 1:49 PM EDT)

Stifel analyst Rick Wise raised the price target on Boston Scientific (NYSE: BSX) to $83.00 (from $70.00) while maintaining a Buy rating.

The analyst commented: 'Looking ahead to 2024 and beyond, could BSX continue outperforming their LRP and our... More

Boston Scientific (BSX) pipeline strength fuels quarterly earnings beat

Boston Scientific (NYSE: BSX) reported a significant earnings and revenue beat for the first quarter of 2024, exceeding analyst expectations and providing an optimistic outlook for the future. The company's shares rose by 2.7% as the market responded positively to the news.

The medical device maker announced an adjusted EPS of $0.56, surpassing the consensus estimate of $0.51. Revenue for the quarter was also higher than anticipated, coming in at $3.86 billion against the expected $3.68 billion. These figures... More

Boston Scientific (BSX) Tops Q1 EPS by 5c; Guides Above Views

Boston Scientific (NYSE: BSX) reported Q1 EPS of $0.56, $0.05 better than the analyst estimate of $0.51. Revenue for the quarter came in at $3.86 billion versus the consensus estimate of $3.68 billion.

GUIDANCE:

Boston Scientific sees Q2 2024 EPS of $0.57-$0.59, versus the consensus of... More

Boston Scientific (BSX) May option implied volatility into quarter results

Boston Scientific (NYSE: BSX) May call option implied volatility is at 27, June is at 23; compared to its 52-week range of 17 to 33 into the expected release of quarter results before the bell on April 24.